# A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

> **NCT05902988** · PHASE1,PHASE2 · RECRUITING · sponsor: **Volastra Therapeutics, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Solid Tumor
- High Grade Serous Adenocarcinoma of Ovary
- Squamous Non-small-cell Lung Cancer
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Ovarian Carcinosarcoma
- Uterine Carcinosarcoma
- Uterine Serous Carcinoma
- Endometrium Cancer
- Chromosomal Instability

## Interventions

- **DRUG:** VLS-1488

## Key facts

- **NCT ID:** NCT05902988
- **Lead sponsor:** Volastra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05902988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05902988, "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05902988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*